59 results
425
EX-10.1
NTBL
Notable Labs Ltd
2 Oct 23
Business combination disclosure
5:31pm
States.
(iii)
US $1,500,000 for the first commercial sale of the Covered Product in the European Union.
(iv)
US $750,000 for the first commercial sale
8-K
EX-10.1
NTBL
Notable Labs Ltd
2 Oct 23
Other Events
5:30pm
States.
(iii)
US $1,500,000 for the first commercial sale of the Covered Product in the European Union.
(iv)
US $750,000 for the first commercial sale
424B3
NTBL
Notable Labs Ltd
2 Oct 23
Prospectus supplement
5:29pm
commercial sale of the Covered Product in the European Union.
(iv)
US $750,000 for the first commercial sale of the Covered Product in Japan.
Buyer
424B3
vdt16
5 Sep 23
Prospectus supplement
6:02pm
S-4/A
1it kogxcjvh8
30 Jun 23
Registration of securities issued in business combination transactions (amended)
4:38pm
S-4
d00zgirgcn6
11 May 23
Registration of securities issued in business combination transactions
9:09am
S-4
EX-10.9
1erjyu
11 May 23
Registration of securities issued in business combination transactions
9:09am
6-K
EX-99.3
zz8iedw 4f0o901jeh
17 May 22
VBL Therapeutics Reports First Quarter 2022 Financial Results
7:00am
6-K
EX-1.1
ib4q6 ovabfnzy31pop
11 Feb 22
Current report (foreign)
5:29pm
424B5
dys00v c5
11 Feb 22
Prospectus supplement for primary offering
5:28pm
6-K
EX-99.3
zuplcys3u5
15 Nov 21
VBL Therapeutics Reports Third Quarter 2021 Financial Results
7:00am
6-K
vxk0zk5l
16 Aug 21
Current report (foreign)
7:00am
6-K
ak4 pa2alwyuyc2v
11 May 21
Current report (foreign)
7:00am
POS AM
xni0h
19 Apr 21
Prospectus update (post-effective amendment)
5:17pm